Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Si-544 in Adults With Atopic Dermatitis
NCT05383378Phase 1Completed
- Sponsor
- selectION, Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing si-544 with Placebo (2 arms). Primary endpoints: Adverse events (AEs) at Day 106, Change from Baseline in hematology parameter platelets at Day 106 and 13 more. Started Aug 2022; status: completed.
02
Drugs
si-544
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05383378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383378.